Skip to content
MarketScale
‹ Back to IndustriesSciences

The Future of Fiber Optics Is Looking Bright

What kind of industry could potentially have a compound annual growth rate (CAGR) of around 9% over the next decade? The answer: the global fiber optics market. That would mean by 2025, the fiber optic market could be worth approximately $7.52 billion. There is little question that the future is looking bright for fiber optics….

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · Promoted Content
Share
The Future of Fiber Optics Is Looking Bright

Key takeaways

01

What kind of industry could potentially have a compound annual growth rate (CAGR) of around 9% over the next decade?

02

The answer: the global fiber optics market.

03

That would mean by 2025, the fiber optic market could be worth approximately $7.52 billion.

What kind of industry could potentially have a compound annual growth rate (CAGR) of around 9% over the next decade? The answer: the global fiber optics market. That would mean by 2025, the fiber optic market could be worth approximately $7.52 billion. There is little question that the future is looking bright for fiber optics.

What will drive all of this growth? The primary mainspring is the need for high bandwidth in the maritime environment, the healthcare industry, technological advancements, and upgrades to current systems. Increasing demand for high-speed internet is driving the demand for high-speed fiber optics systems, including higher-capacity optical fibers and system components like optical amplifiers. Everyone wants more bandwidth, and fiber optics is proving it can deliver.

Fiber Optics, VDSL, and Home Demand for High-Speed Internet

Rising internet speeds has led to an increase in demand for Fiber to the Home (FTTH). If anything can slow the growth of fiber optics, though, it’s competition from the latest development in DSL to VDSL. Glass and plastic optical fibers are competing against copper wire, but with the rising prices of copper, it is likely that fiber optics will remain competitive.

Temperature Sensors

One place where fiber optics remains vital is the temperature sensors market. This market is expected to grow by nearly 6% over the next five years, from $5.62 billion in 2018 to $7.48 billion in 2023. Growth is expected from their use in the chemical, consumer electronics (like wearables and smartphones), oil and gas, energy and power, and automotive industries.

Optical Amplifiers

Optical amplifiers are a central component to fiber optics systems, and as the demand for fiber optics increases, so will demand for optical amplifiers. In fact, it’s predicted that the optical amplifier market will grow by around $936 million between 2019 and 2023, averaging a 9% CAGR that keeps step with the projected 9% growth for fiber optical systems. Long- and ultra-long-haul (from cities to continents) networks that amplify signal transmission over long distances will likely be a key growth driver in this sector.

Let Fiberguide Industries Be Your Guide to a Fiber Optical Future

For more than three decades, Fiberguide Industries has been a reliable, long-term strategic partner with OEM manufacturers in providing efficient, cost-effective, practical fiber optic solutions engineered to meet their specific needs. Specializing in manufacturing large core specialty optical fiber and high temperature metalized optical fibers, Fiberguide packages their fibers in a variety of assemblies/bundles to meet the requirements of diverse optical power delivery and optical sensing applications. With corporate headquarters and fiber manufacturing located in Stirling, New Jersey, applications engineering, component, and assembly manufacturing in Caldwell, Idaho, and a sales office and manufacturing in Shanghai, China, Fiberguide Industries is well positioned to serve the needs of their customers globally.

To learn more about how Fiberguide can help guide you to better optical fiber solutions, contact us at https://www.fiberguide.com/ today!

About the author

PC
Promoted Content

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512